Immunotherapy with checkpoint inhibitors like pembrolizumab shows significant activity in triple-negative breast cancer.

“and interestingly we usually use them before the surgery we can come back to talking about that in what we call a Neo adant approach which is the same idea as adant therapy drug therapy to mop up cancer everywhere in the body but actually given before the surgery to shrink the tumor and to um allow the patient to get the effective treatment that goes everywhere in the body”

“but the biggest new thing has been immunotherapy and I'm I'm sure in other cancer podcasts you've talked about the so-called checkpoint Inhibitors drugs like pembrolizumab and others that have proven very active in a lot of different tumor types in breast cancer the data are most comping for these drugs in triple negative breast cancers where we um have shown that they can uh reduce the risk of cancer recurrence”

“and interestingly we usually use them before the surgery we can come back to talking about that in what we call a Neo adant approach which is the same idea as agant therapy drug therapy to mop up cancer everywhere in the body but actually given before the surgery to shrink the tumor and to um allow the patient to get the effective treatment that goes everywhere in the body”